Progressive Care Inc (RXMD)

[ndww42]

$RXMD UPCOMING CATALYSTS / NEWS

It's been amazing to watch RXMD in action. This will absolutely test .26 again no doubt about it. I'd like to reference the Mobb Deep song entitled "Shook Ones" for the recent dip. We will recover with conviction because the fundamentals support it.

With our recent .35 target we will easily make it into the .30s very soon.

Just looking over the below items is enough for me to continue to buy this into dollars.

The CEO just completed a Wallstreet interview where she said we will be going to NASDAQ and NET revenues will be at least 75M very soon.

Everything else has been executed beautifully by the company so I can without a doubt see us doing what Shital said.

Trust the fundamental analysis and realize that NASDAQ is the future. There will not be any discount shares available (as there are today) once we go to the big boards.

I've been buying from .05 to .26 to .12 and back up again.

We are adjusting and today's rally proved the bulls are in control.

February NET revenues: Week of March 12th or 19th or sooner - should be record net revenues again with possibly our second 2M+ month. We're looking at getting these either Friday (March 16) or the week after.

Investor conferences: Progressive Care Inc. will be presenting at the 26th Annual Investor Conference: The Wall Street Investor Forum on March 22nd. Last time the company attended an investor conference there was BIG TIME buying that followed. With 2 years of audited financials coming by 3/31 I predict us blowing past .26 like a breeze.

Acquisition details: With the latest announcement of the company's intent to purchase a pharmacy in Palm Beach County, we will see additional details around this purchase and what it means on the revenue side.

Audited Annual Report: Report is due 3/31 and will be the second audited year. Having two years of audited fins is the gold standard for institutional monies to flow in.

Conference call for shareholders: This occurs every quarter. Should happen around the release of the annual report.

March Numbers: Week of April 12th or 19th - should be record revenues again with possibly our third 2M+ month.

Additional technology partnerships / contracts: Progressive care is both a healthcare services and technology company. Expect additional PRs and contracts stating new revenues streams

Institutional buying: We've had what looks to be institutional buying recently and I would venture to guess we will receive more news about institutions covering us and major investments after we have our two years of audited financials in April.

Institutional stock coverage: Shital has made it clear that she'd like to have coverage of the stock by institutional analysts. We are seeing more and more signs of this and will hear more about it soon IMO.

Online Pharmacy / e-Commerce: With the news of Bitcoin and Amazon looking to get into the pharmacy space, expect additional news on RXMD about becoming a major online pharmacy.

CBD / MJ / HEMP: One of the latest major developments. Additional news about CBD and MJ will most likely be coming out in the next couple of months. They already stated they will have in-house compounding and R&D! This will boost sales big time as customers would like to see alternatives to addictive pain pills.

Tech / Tele-Pharm news: With the latest development of this being a tech play, we should hear more about their plan for tele-Pharmco and also we should hear from our NASDAQ independent board member on the latest developments.

Investor conferences to attract institutional investors: They will most likely PR these events over the coming months.

New 340B contracts: Over the next month or two we will most likely hear about new 340B contracts from multiple partners

New Long term care facility relationships: The company continues to be active in the community with doctors, patients and long term facilities. Expect additional partnerships on this front.

Achieve accreditation for non-sterile compounding: One the company's stated goals for 2018 is receiving accreditation for non-sterile compounding. This will actually allow them to make more money with more of a backing.

Traditional financing: Expect news of traditional financing over the coming year.

Opening more Pharmco Pharmacy Resource Centers in retirement and long term care communities: Another 2018 goal of the company. They will announce more resource centers to again strengthen their relationships in the community.

More out of state licenses: They've already obtained 14 state licenses where they can do business and planning to expand to more states. We may hear more about these revenue streams as they add to the bottom line.

Purdue sales rep team: We should be hearing more about the Purdue pharma sales force to join the team for conducting out of state sales

Aggressive expansion / M&A: We should be seeing additional PBM contracts related to their recent acquisition. I also believe we will hear more about additional acquisitions and other partnerships.

NASDAQ uplisting: With traditional financing, 2 locations and a much higher PPS, I expect to start to hear more about the company's plan to uplist to NASDAQ.